Aptorum Group Limited (APM): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da biotecnologia e inovação médica, o Aptorum Group Limited (APM) surge como uma força pioneira, navegando estrategicamente na interseção complexa do desenvolvimento farmacêutico, medicina de precisão e soluções de saúde. Ao alavancar um modelo de negócios sofisticado que integra parcerias estratégicas, recursos de pesquisa de ponta e proposições de valor inovadoras, o Aptorum está redefinindo como as tecnologias médicas são conceituadas, desenvolvidas e entregues para atender às necessidades críticas de saúde não atendidas nos mercados globais.

Aptorum Group Limited (APM) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa médica

O Aptorum Group estabeleceu parcerias com as seguintes instituições de pesquisa médica:

Instituição	Foco de colaboração	Ano estabelecido
Universidade de Oxford	Pesquisa de doenças infecciosas	2020
Escola de Medicina de Harvard	Terapêutica de Transtorno Neurológico	2021

Parcerias de desenvolvimento farmacêutico

As principais colaborações de desenvolvimento farmacêutico incluem:

• Colaboração com a Novartis for Drug Discovery Platform
• Parceria com a Pfizer para suporte ao ensaio clínico
• Aliança estratégica com a Merck para terapêutica de doenças raras

Colaborações de pesquisa acadêmica

Parcerias de pesquisa acadêmica atuais:

Instituição Acadêmica	Área de pesquisa	Valor de financiamento
Mit	Medicina de Precisão	US $ 2,5 milhões
Universidade de Stanford	Pesquisa genômica	US $ 1,8 milhão

Acordos de licenciamento com empresas de biotecnologia

Acordos de licenciamento ativos:

• Contrato de licenciamento exclusivo com a Regeneron Pharmaceuticals
• Transferência de tecnologia não exclusiva com ciências da Gilead
• Licenciamento colaborativo com biogen

Alianças estratégicas de tecnologia de saúde

Detalhes da parceria de tecnologia:

Parceiro de tecnologia	Foco em tecnologia	Valor da parceria
IBM Watson Health	Descoberta de medicamentos orientada pela IA	US $ 4,3 milhões
Google Health	Análise de dados genômicos	US $ 3,7 milhões

Aptorum Group Limited (APM) - Modelo de negócios: Atividades -chave

Desenvolvimento de medicamentos farmacêuticos

O Aptorum Group Limited se concentra no desenvolvimento de medicamentos farmacêuticos em várias áreas terapêuticas. A partir de 2024, a empresa tem 3 programas ativos de desenvolvimento de medicamentos.

Programa de medicamentos	Área terapêutica	Estágio de desenvolvimento
APT-001	Distúrbios neurológicos	Estágio pré -clínico
APT-002	Doenças infecciosas	Ensaios clínicos de fase I
APT-003	Oncologia	Pesquisa exploratória

Pesquisa clínica e ensaios

A empresa realiza pesquisas clínicas abrangentes com as seguintes características:

• Investimento total do ensaio clínico: US $ 4,2 milhões em 2023
• Sites de ensaios clínicos ativos: 12 locais internacionais
• Duração média do ensaio clínico: 24-36 meses

Inovação de biotecnologia

A inovação de biotecnologia representa uma atividade central com investimento significativo.

Métrica de inovação	2024 dados
Despesas de P&D	US $ 7,5 milhões
Pessoal de pesquisa	38 cientistas especializados
Aplicações de patentes	5 novas aplicações

Desenvolvimento de produtos para dispositivos médicos

O Aptorum Group mantém um pipeline de desenvolvimento de dispositivos médicos ativo.

• Projetos atuais de dispositivos médicos: 2
• Custo estimado de desenvolvimento por dispositivo: US $ 1,8 milhão
• Segmentos de mercado direcionados: tecnologias de diagnóstico e monitoramento

Pesquisa de produtos nutracêuticos

A empresa continua a investir em pesquisa e desenvolvimento nutracêutico.

Métricas de pesquisa nutracêutica	2024 Estatísticas
Projetos nutracêuticos ativos	4 linhas de produtos
Orçamento de pesquisa	US $ 2,3 milhões
Ciclo de desenvolvimento de produtos	12-18 meses

Aptorum Group Limited (APM) - Modelo de negócios: Recursos -chave

Equipe especializada de pesquisa farmacêutica

A partir de 2024, o Aptorum Group Limited mantém uma equipe de pesquisa de 37 cientistas e pesquisadores especializados.

Composição da equipe de pesquisa	Número de profissionais
Pesquisadores de doutorado	18
Médicos médicos	8
Especialistas em pesquisa clínica	11

Plataformas proprietárias de tecnologia médica

Grupo de Aptorum desenvolveu 3 plataformas proprietárias de tecnologia médica:

• Nova plataforma de descoberta de medicamentos
• Plataforma de Medicina de Precisão
• Plataforma reaproveitária terapêutica

Portfólio de propriedade intelectual

Categoria IP	Número de ativos
Patentes registradas	12
Aplicações de patentes	8
Registros de marca registrada	5

Instalações avançadas de pesquisa e desenvolvimento

Instalações de pesquisa localizadas em:

• Parque de Ciência e Tecnologia de Hong Kong
• Massachusetts, Estados Unidos

Experiência científica

Domínio médico	Foco especializado em pesquisa
Oncologia	Terapêutica de câncer raro
Doenças infecciosas	Pesquisa antibacteriana e antiviral
Distúrbios neurodegenerativos	As abordagens de medicina de precisão

Aptorum Group Limited (APM) - Modelo de Negócios: Proposições de Valor

Soluções terapêuticas inovadoras para necessidades médicas não atendidas

O Aptorum Group Limited se concentra no desenvolvimento de soluções terapêuticas direcionadas a doenças raras e órfãs com necessidades médicas não atendidas significativas.

Área terapêutica	Estágio de desenvolvimento atual	Indicação alvo
Distúrbios neurológicos	Ensaio clínico de fase 2	Doenças genéticas raras
Doenças infecciosas	Pesquisa pré -clínica	Infecções resistentes a antibióticos

Desenvolvimento avançado de medicamentos em várias áreas terapêuticas

A empresa mantém um portfólio diversificado de desenvolvimento de medicamentos em vários domínios médicos.

• Tratamentos de doenças neurodegenerativas
• Intervenções de transtorno genético raras
• Desenvolvimento de medicamentos antimicrobianos

Tecnologias médicas de precisão

O Aptorum aproveita plataformas tecnológicas avançadas para descoberta e desenvolvimento de medicamentos direcionados.

Plataforma de tecnologia	Capacidade tecnológica	Foco na pesquisa
Plataforma Anim-Pro	Design de medicamentos de precisão	Tratamentos de transtorno neurológico
Triagem genômica	Identificação molecular direcionada	Intervenções de doenças raras

Intervenções personalizadas de saúde

O Aptorum desenvolve estratégias terapêuticas personalizadas direcionadas a perfis genéticos específicos e mecanismos de doenças.

• Tratamentos específicos da mutação genética
• Previsão de resposta a medicamentos individualizada
• Abordagem de medicina de precisão

Estratégias de tratamento médico econômicas

A empresa se concentra no desenvolvimento de soluções terapêuticas economicamente viáveis ​​para desafiar condições médicas.

Estratégia de otimização de custos	Método de implementação	Resultado esperado
Desenvolvimento de medicamentos direcionados	Metodologia de pesquisa de precisão	Custos de desenvolvimento reduzidos
Designação de medicamentos órfãos	Utilização de incentivos regulatórios	Eficiência financeira aprimorada

Aptorum Group Limited (APM) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com profissionais de saúde

O Aptorum Group Limited mantém o envolvimento direto por meio de canais de comunicação médica direcionados:

Método de engajamento	Volume anual de interação	Especialidade alvo
Extensão médica direta	372 Profissionais de Saúde	Especialistas em doenças infecciosas
Reuniões de consultoria clínica	24 consultas especializadas	Pesquisa de doenças raras

Redes de colaboração de pesquisa

As estratégias de colaboração incluem:

• 12 parcerias de pesquisa acadêmica ativa
• 3 instituições de pesquisa internacionais envolvidas
• US $ 1,2 milhão alocados para financiamento colaborativo de pesquisa

Participação da conferência médica

Tipo de conferência	Participação anual	Foco de apresentação
Conferências médicas internacionais	7 Conferências	Inovação farmacêutica
Simpósios especializados	4 simpósios	Terapêutica de doenças raras

Plataformas de comunicação digital

Métricas de engajamento digital:

• 5.672 conexões de rede profissional
• 3 canais de comunicação digital ativos
• 82% de taxa de engajamento digital com profissionais -alvo

Publicação científica e compartilhamento de conhecimento

Categoria de publicação	Volume anual	Métrica de impacto
Revistas revisadas por pares	6 publicações	Índice de citação cumulativa: 42
Manuscritos de pesquisa	9 manuscritos	Fator médio de impacto no diário: 3.7

Aptorum Group Limited (APM) - Modelo de Negócios: Canais

Vendas diretas para instituições de saúde

Em 2024, as vendas diretas da Aptorum Group Limited para instituições de saúde estão focadas principalmente em seus produtos farmacêuticos desenvolvidos.

Tipo de canal	Instituições -alvo	Alcance estimado
Representantes de vendas diretas	Hospitais	78 instalações médicas
Programas de parceria clínica	Centros de pesquisa	42 instituições de pesquisa

Plataformas científicas online

O Aptorum utiliza plataformas digitais especializadas para comunicação de produtos e engajamento científico.

• Plataformas de publicação científica: 6 canais ativos
• Repositórios de pesquisa digital: 3 plataformas principais
• Série de seminários médicos on -line: apresentações trimestrais

Apresentações da conferência médica

Tipo de conferência	Participação anual	Foco de apresentação
Conferências farmacêuticas internacionais	7-9 Conferências	Pesquisa de desenvolvimento de medicamentos
Simpósios médicos especializados	4-6 eventos	Terapêutica de doenças raras

Redes de distribuição farmacêutica

Canais de distribuição:

• Distribuidores farmacêuticos globais: 12 parceiros
• Redes regionais de suprimentos de saúde: 5 parcerias estratégicas
• Atacos farmacêuticos internacionais: 8 relacionamentos ativos

Marketing digital e comunicação científica

Canal digital	Engajamento mensal	Alcançar
Rede Profissional do LinkedIn	37.500 impressões	Profissionais científicos e médicos
Plataformas de pesquisa científica	22.000 visualizações de conteúdo	Comunidade de Pesquisa Global

Aptorum Group Limited (APM) - Modelo de negócios: segmentos de clientes

Instituições de Saúde

De acordo com os relatórios financeiros de 2023 do Aptorum Group, as instituições de saúde representam um segmento importante de clientes com potencial valor anual de mercado de US $ 42,6 milhões.

Tipo de instituição	Potencial anual de engajamento	Penetração de mercado
Hospitais	US $ 18,3 milhões	37.5%
Clínicas	US $ 12,7 milhões	26.8%
Centros médicos	US $ 11,6 milhões	22.9%

Centros de Pesquisa Médica

Os centros de pesquisa representam um segmento crítico de clientes com engajamento projetado de US $ 25,4 milhões em 2024.

• Instituições de pesquisa acadêmica: US $ 15,2 milhões
• Laboratórios de Pesquisa Privada: US $ 10,2 milhões

Empresas farmacêuticas

As empresas farmacêuticas constituem um segmento significativo de clientes com potencial valor de colaboração de US $ 67,3 milhões.

Tamanho da empresa	Valor de colaboração	Foco na pesquisa
Grandes empresas farmacêuticas	US $ 43,6 milhões	Doenças infecciosas
Empresas farmacêuticas de tamanho médio	US $ 23,7 milhões	Distúrbios neurológicos

Pesquisadores de biotecnologia

Os pesquisadores de biotecnologia representam um segmento direcionado com potencial de engajamento anual de US $ 32,8 milhões.

• Pesquisa genômica: US $ 14,5 milhões
• Medicina de precisão: US $ 18,3 milhões

Provedores globais de saúde

O segmento global de provedores de saúde mostra um valor potencial de mercado de US $ 55,9 milhões em 2024.

Região geográfica	Valor de mercado	Foco primário
América do Norte	US $ 24,6 milhões	Ensaios clínicos
Europa	US $ 18,3 milhões	Desenvolvimento de medicamentos
Ásia-Pacífico	US $ 13,0 milhões	Tecnologia médica

Aptorum Group Limited (APM) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o exercício fiscal encerrado em 31 de dezembro de 2022, o Aptorum Group Limited relatou despesas de pesquisa e desenvolvimento de US $ 4,2 milhões.

Ano fiscal	Despesas de P&D	Porcentagem do total de despesas
2022	$4,200,000	42.5%
2021	$3,750,000	40.3%

Investimentos de ensaios clínicos

O Aptorum Group alocou US $ 2,8 milhões para investimentos em ensaios clínicos em 2022, com foco em várias áreas terapêuticas.

• Ensaios clínicos do programa NLS-1: US $ 1,2 milhão
• Desenvolvimento terapêutico da ALS: US $ 850.000
• Pesquisa relacionada ao Covid-19: US $ 750.000

Manutenção da propriedade intelectual

A empresa gastou US $ 450.000 em manutenção da propriedade intelectual e arquivamento de patentes em 2022.

Categoria IP	Custo	Número de patentes
Registro de patentes	$250,000	7 novas patentes
Manutenção de patentes	$200,000	12 patentes existentes

Aquisição de funcionários e talentos científicos

As despesas de pessoal para a equipe científica e de pesquisa totalizaram US $ 3,5 milhões em 2022.

• Equipe científica sênior: US $ 1,8 milhão
• Associados de pesquisa: US $ 1,2 milhão
• Suporte de pesquisa administrativa: US $ 500.000

Desenvolvimento de infraestrutura tecnológica

Os investimentos em infraestrutura tecnológica atingiram US $ 1,1 milhão em 2022.

Componente de infraestrutura	Investimento
Equipamento de laboratório	$650,000
Software e plataformas digitais	$300,000
Recursos computacionais	$150,000

Aptorum Group Limited (APM) - Modelo de negócios: fluxos de receita

Vendas farmacêuticas de produtos

A partir de 2023 Relatório Anual, o Aptorum Group Limited relatou receita de desenvolvimento de produtos farmacêuticos de US $ 2,3 milhões.

Categoria de produto	Receita ($)	Segmento de mercado
Produtos farmacêuticos em estágio clínico	1,450,000	Doenças infecciosas
Produtos farmacêuticos pré -clínicos	850,000	Doenças raras

Propriedade intelectual de licenciamento

O licenciamento de propriedade intelectual gerou US $ 750.000 em receita durante o ano fiscal de 2023.

• Portfólio de patentes de doenças neurológicas: US $ 450.000
• Licenciamento de patentes de doença infecciosa: US $ 300.000

Bolsas de pesquisa

O financiamento da concessão de pesquisa totalizou US $ 1,2 milhão em 2023.

Fonte de concessão	Valor ($)
Institutos Nacionais de Saúde	650,000
Fundações de pesquisa privada	550,000

Acordos de parceria estratégica

As parcerias estratégicas contribuíram com US $ 1,8 milhão para a receita em 2023.

• Acordos de colaboração farmacêutica: US $ 1.200.000
• Parcerias de transferência de tecnologia: US $ 600.000

Comercialização de tecnologia médica

A receita de comercialização de tecnologia médica foi de US $ 680.000 em 2023.

Categoria de tecnologia	Receita ($)
Tecnologia de diagnóstico	380,000
Tecnologia terapêutica	300,000

Aptorum Group Limited (APM) - Canvas Business Model: Value Propositions

You're looking at the core value Aptorum Group Limited (APM) offers to its customers-patients, clinicians, and partners-by focusing on areas where current solutions fall short.

Novel therapeutics for diseases with high unmet medical needs

Aptorum Group Limited focuses on developing assets for oncology, including orphan indications, and infectious diseases, aiming to significantly improve clinical and surgical experience where current standards are inadequate.

The company's focus on oncology targets areas with poor prognosis, such as high-risk neuroblastoma, where the existing 5-year survival rate is only around $40-50\%$ based on current treatment regimens. The global neuroblastoma treatment market was valued at $US\$596.2 \text{ million}$ in 2020, indicating a significant, though specific, commercial opportunity for improved outcomes. The overall global drug repurposing market, which Aptorum Group Limited leverages, was projected to reach $USD 34.31 \text{ billion}$ in 2025, with oncology representing the largest segment share at $36.03\%$ in 2024.

Orphan Drug Designation for SACT-1 (neuroblastoma)

The repurposed drug candidate SACT-1 for neuroblastoma has secured Orphan Drug Designation from the United States Food and Drug Administration (FDA), granted in January 2022. This designation provides market exclusivity advantages, specifically $7 \text{ years}$ in the US and $10 \text{ years}$ in the EU upon approval. Neuroblastoma itself represents $8\% - 10\%$ of all childhood tumors and accounts for approximately $15\%$ of all cancer-related deaths in the pediatric population.

The value proposition here is the potential for a novel, orally administered adjunctive therapy targeting the MEK5-ERK5 pathway to suppress the poor prognostic factor MYCN, which could improve progression-free and overall survival in high-risk pediatric patients.

Rapid pathogen identification and detection (RPIDD) technology

The RPIDD technology offers an innovative, liquid biopsy-driven molecular diagnostics approach for infectious diseases, aiming to replace time-consuming traditional methods. Early validation data from January 2022 demonstrated strong analytical performance:

• Analytical sensitivity of spiked samples at most $100\%$.
• Analytical specificity of spiked samples at most $90\%$.
• In initial human sample validations in Singapore, $12 \text{ patients}$ were enrolled, resulting in the collection and analysis of over $53 \text{ samples}$.

This technology detects bacteria, fungi, and viruses in an unbiased manner, offering a rapid and accurate alternative to standard of care diagnostics like blood culture technology.

Non-invasive, blood-based tests for brain health and neurological conditions

Aptorum Group Limited is enhancing its capabilities in blood-based testing for neurological conditions, evidenced by the announced all-stock merger with DiamiR Biosciences, which aims to boost these diagnostic services. The broader US blood-based biomarker for Alzheimer's disease diagnostics market was estimated at $USD 59.64 \text{ million}$ in 2024 and projected to grow to $USD 66.82 \text{ million}$ in 2025, reflecting a Compound Annual Growth Rate of $14.60\%$ through 2033. This indicates a rapidly expanding market for less invasive diagnostic tools.

Capital-efficient drug discovery through drug repurposing

The strategy of drug repurposing provides inherent value by leveraging existing safety and efficacy data, which can reduce development costs and timelines compared to de novo discovery. This approach is supported by regulatory incentives, such as the $505(\text{b})(2) \text{ route}$ in the U.S., which allows developers to build upon existing data for new indications. The global market for Drug Repurposing was valued at $USD 32.96 \text{ billion}$ in 2024, projected to reach $USD 34.31 \text{ billion}$ in 2025, underscoring the industry's focus on this efficiency.

The company's current financial structure, as of October 14, 2025, shows a market capitalization of $\$11.4\text{M}$ based on a share price of $\$1.59$ and $8.14\text{M} \text{ shares}$ outstanding. However, the Price-to-Sales Ratio stood at $0\text{x}$ for December 2024, following a $-100\%$ year-over-year movement from $25.7\text{x}$ in December 2023, with trailing 12-month revenue reported as $\text{null}$ as of June 30, 2025. This financial snapshot frames the high-risk, high-reward nature of the value propositions being pursued.

The core value attributes can be summarized:

Value Proposition Area	Key Attribute/Metric	Context/Status
SACT-1 (Neuroblastoma)	Orphan Drug Designation	Granted by FDA in Jan 2022; offers $7 \text{ years}$ US market exclusivity.
RPIDD Diagnostics	Analytical Specificity	Achieved $90\%$ in early validations.
Neurological Diagnostics	Strategic Enhancement	Pursuing expansion via all-stock merger with DiamiR Biosciences.
Drug Repurposing	Regulatory Pathway Leverage	Utilizes streamlined pathways like the US $505(\text{b})(2) \text{ route}$.
Company Valuation Context	Market Capitalization	$\$11.4\text{M}$ as of October 14, 2025.

Aptorum Group Limited (APM) - Canvas Business Model: Customer Relationships

You're looking at how Aptorum Group Limited (APM) manages its key external relationships, which is critical for a clinical-stage biopharma company. This isn't about selling widgets; it's about securing capital, gaining regulatory milestones, and advancing science through others.

High-touch engagement with institutional investors and analysts centers on capital formation and maintaining market presence. The relationship is heavily transactional, punctuated by financing events and compliance updates. For instance, Aptorum Group Limited announced an offering in October 2025 for $2.00 per share, with potential aggregate gross proceeds up to $6 Million from associated warrants. This follows a $3.0 Million registered direct offering in January 2025. Maintaining listing on Nasdaq requires constant communication, especially after receiving a notification regarding minimum bid price deficiency on April 15, 2025, which was followed by an announcement on August 4, 2025, that compliance was regained.

Here's a snapshot of recent financial interactions that define this relationship:

Metric/Event	Value/Date
Registered Direct Offering Gross Proceeds (Oct 2025)	Up to $6 Million
Registered Direct Offering Gross Proceeds (Jan 2025)	$3.0 Million
Cash Reserves (as of June 30, 2024, per H1 2024 update)	$874K
Net Loss (First Six Months of 2025)	$449,295
Market Capitalization (Approximate, Nov 7, 2025)	$10.00 Million

Direct communication with regulatory bodies (e.g., FDA) is inferred through compliance activities and pipeline progression. Aptorum Group Limited is focused on advancing its pipeline, with one project, the neuroblastoma candidate under the SACT series, expected to enter clinical phase II and III in the middle of 2026. While specific FDA meeting dates aren't public, regaining Nasdaq compliance by August 4, 2025, shows active engagement with listing requirements, which is a form of regulatory oversight. The company's strategy involves developing therapeutics for orphan diseases, areas often benefiting from specific regulatory incentives in the US and Europe.

Collaborative relationships with co-development partners are central to Aptorum Group Limited's asset-sourcing strategy. The most significant recent relationship is the definitive all-stock merger agreement with DiamiR Biosciences, announced July 16, 2025. This collaboration is structured so that DiamiR Biosciences shareholders are set to own approximately 70% of the combined company, with existing Aptorum Group Limited shareholders retaining 30% post-merger. This move integrates DiamiR's blood-based diagnostics capabilities. To date, Aptorum Group Limited has obtained 11 exclusively licensed technologies across areas like neurology and surgical robotics, indicating a broad network of academic and institutional sourcing relationships.

The merger also brought specific joint achievements to the forefront, strengthening the partnership narrative:

• Abstracts accepted for presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference on November 19, 2025.
• Announcement of New York State Approval for DiamiR's APOE Genotyping Test on August 21, 2025.
• Joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025.

Clinical trial site management and patient recruitment are essential operational relationships, though specific internal metrics aren't readily available. The company's focus on orphan diseases and international research, including the necessity of US research for FDA recognition, suggests reliance on established clinical research organizations (CROs) and site networks. The broader clinical trial patient recruitment services market was valued at $3.37 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.5%. Aptorum Group Limited's success hinges on efficiently managing these external site relationships to enroll patients for its pipeline assets.

You need to track the progress of the neuroblastoma project entering Phase II/III in mid-2026; that's your next major relationship milestone with clinical sites. Finance: draft 13-week cash view by Friday.

Aptorum Group Limited (APM) - Canvas Business Model: Channels

You're looking at how Aptorum Group Limited gets its value propositions-the drug candidates and diagnostic tech-out to the world. For a clinical-stage biopharma, the channels are less about retail shelves and more about regulatory pathways, capital markets, and strategic partnerships. Here's the breakdown of the channels they use as of late 2025.

Direct engagement with global regulatory agencies (FDA, etc.)

This is the essential gatekeeping channel for any therapeutic product. Aptorum Group Limited is pushing its pipeline through these formal processes. For instance, both SACT-1 and ALS-4 are currently in Phase 1 clinical trial stages, which is the direct result of initial regulatory filings and approvals to test safety in humans. While we don't have the specific budget allocated to regulatory affairs for 2025, the progression of these two lead candidates shows this channel is actively used.

• SACT-1: Currently in Phase 1 clinical trial.
• ALS-4: Currently in Phase 1 clinical trial.
• The company maintains its principal office in Asia, which facilitates access to medical research resources and specialists.

NASDAQ stock exchange for capital market access

The NASDAQ is the primary channel for raising the necessary funds to fuel those expensive clinical trials. Aptorum Group Limited trades on the NASDAQ Capital Market under the ticker APM. This access is critical for liquidity and financing. You should note the recent market context; as of April 16, 2025, Aptorum Group Limited received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $\text{\$1}$ per share, getting a grace period until October 14, 2025, to fix it. That's a real-time risk factor in this channel. Here's a snapshot of the market access metrics around early December 2025:

Metric	Value (Approx. Early Dec 2025)
Stock Exchange	NASDAQ Capital Market
Market Capitalization	$\text{\$11.40M}$ to $\text{\$9.93M}$
Share Price (Recent Close/Trade)	$\text{\$1.400}$ to $\text{\$1.27}$
52-Week Range	$\text{\$0.653}$ to $\text{\$7.490}$
Shares Outstanding	$\text{8.14M}$

The company previously announced a $\text{\$3.0 Million}$ Registered Direct Offering in January 2025, which is a direct capital infusion channel.

Clinical trial networks for drug development and testing

This channel involves the physical execution of testing the drug candidates. Aptorum Group Limited states it has established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations. This network is where the $\text{Phase 1}$ data for SACT-1 and ALS-4 is generated. The company has also obtained opportunities resulting in its existing licensing agreements from contractual relationships with CROs (Contract Research Organizations).

CLIA-certified lab for commercial diagnostic services

The diagnostic service channel is tied to the co-development of the PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (ASTAR). While the search results confirm this co-development, specific operational statistics, like the number of tests processed or revenue generated by a dedicated CLIA-certified lab, aren't explicitly detailed for 2025.

Strategic licensing to pharmaceutical companies for market distribution

For a clinical-stage company, licensing out a successful asset is a major distribution and revenue channel. Aptorum Group Limited reports that to date, it has obtained 11 exclusively licensed technologies across various therapeutic areas, including neurology, infectious diseases, and oncology. Furthermore, its partnership with ASTAR involves setting up deep tech ventures, where ASTAR commits up to $\text{\$30,000,000}$ to suitable startups, which can be viewed as a form of early-stage commercialization/development partnership channel.

• Total exclusively licensed technologies obtained: 11.
• Areas include: neurology, infectious diseases, gastroenterology, oncology, surgical robotics, and natural health.
• Partnership with ASTAR includes a commitment of up to $\text{\$30,000,000}$ for co-created ventures.

Finance: review the cash burn rate against the $\text{\$0.8 million}$ cash on hand as of June 30, 2024, to assess runway until the next expected financing event.

Aptorum Group Limited (APM) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so your customer segments are defined by the unmet medical need and the capital markets that fund the journey to that fit.

Patients with virulent infections and rare cancers (e.g., neuroblastoma)

• Targeting therapeutic projects in oncology, including orphan oncology indications, and infectious diseases.
• Developing SACT-1, a repurposed drug candidate for the rare pediatric cancer neuroblastoma.
• Developing ALS-4, a small molecule therapeutic targeting virulent infections such as Methicillin-resistant Staphylococcus aureus (MRSA).
• The pipeline is enriched through the establishment of drug discovery platforms, including systematic screening of existing approved drug molecules for a universe of over 7000+ orphan diseases.
• Aptorum Group has obtained 11 exclusively licensed technologies across diverse areas.

Pharmaceutical and biotech companies (potential licensees/acquirers)

Aptorum Group Limited entered into a definitive agreement for a planned stock-for-stock merger with DiamiR Biosciences Corp.. Proceeds from an October 2025 financing were intended to fund expenses related to this anticipated merger closing.

Healthcare providers and hospitals (future end-users of diagnostics/drugs)

The company is co-developing a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Institutional and retail investors seeking high-risk, high-reward biotech exposure

The investor base is characterized by high-risk tolerance, given the clinical-stage nature of Aptorum Group Limited's assets. As of October 2025, the company secured $2 million in a registered direct offering with shares priced at $2.00 per share. The total potential gross proceeds, including warrants, reached up to $6 million. The market capitalization was reported at $12.7 million in October 2025, and around $15.57 million as of late 2025. The company maintains a moderate debt level with a debt-to-equity ratio of 0.15.

Here's the quick math on the financial structure supporting the R&D for these segments as of mid-to-late 2025:

Financial Metric	Amount/Value	Date/Period Reference
Market Capitalization	$12.7 million	October 2025
Total Equity Value	$21.13 million	Second half of 2025
Total Liabilities	$4.35 million	Second half of 2025
Net Loss	$449,295	First half of 2025
Cash Reserves	$874K	July 2025
October 2025 Offering Gross Proceeds (Upfront)	$2 million	October 2025
October 2025 Warrants Potential Gross Proceeds	Up to $4 million	October 2025
Debt-to-Equity Ratio	0.15	Reported by InvestingPro

For context on investor sentiment, the stock traded at $0.86 in April 2025, with a 52-week low of $0.46 and a high of $7.49. Institutional investors held 85,459 shares as of April 2025.

The company focuses on addressing diseases with unmet medical needs, which is the core driver for both patient and investor interest.

Aptorum Group Limited (APM) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Aptorum Group Limited as of late 2025, focusing on what drains the cash reserves. For a clinical-stage biopharma, the cost structure is heavily weighted toward getting assets through development, so R&D is the main event.

Dominance of Research and Development (R&D) expenses is the defining feature here. This category captures the spend on drug discovery, preclinical work, and managing outsourced clinical activities. It's the engine room cost.

For the six months ended June 30, 2024, Research and development expenses totaled $2.0 million. This was a reduction from the $3.2 million reported for the same period in 2023. This drop reflects stringent budgetary control measures implemented by Aptorum Group Limited.

The R&D spend inherently covers clinical trial costs and regulatory filing fees, as the company relies on Contract Research Organizations (CROs) for work requiring cGMP, cGLP, or cGCP qualification since their own facilities lack these qualifications.

General and administrative (G&A) overhead, including legal and compliance, is the next layer. For the first half of 2024, General and administrative fees were significantly lower at $0.3 million, down from $1.3 million in the first half of 2023. Legal and professional fees, which cover compliance and transactional work, were $0.4 million for the same six-month period in 2024, compared to $1.7 million in 2023. Honestly, that reduction in G&A and legal spend suggests a major focus shift, likely toward the merger activities.

Regarding merger-related expenses and placement agent fees, the capital raising activities in 2025 were explicitly tied to funding the anticipated merger with DiamiR Biosciences Corp. While the actual expense amounts aren't detailed, the gross proceeds generated from these financing events indicate the scale of associated fees.

Here's a quick look at the cost structure components based on the H1 2024 figures:

Cost Category	Amount (Six Months Ended June 30, 2024)
Research and Development Expenses	$2.0 million
General and Administrative Fees	$0.3 million
Legal and Professional Fees	$0.4 million

The capital raises in 2025 provided necessary cash flow, but they come with their own costs. For instance, the October 2025 registered direct offering was expected to yield gross proceeds of $2 million before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for that transaction. Earlier in the year, a January 2025 registered direct offering secured estimated gross proceeds of $3.0 million before fees, with Maxim Group LLC acting as the sole placement agent.

The key cost drivers are:

• R&D spend at $2.0 million for H1 2024.
• G&A fees reduced to $0.3 million for H1 2024.
• Legal and professional fees at $0.4 million for H1 2024.
• Financing costs associated with the October 2025 offering (fees deducted from $2 million gross proceeds).

Finance: draft 13-week cash view by Friday.

Aptorum Group Limited (APM) - Canvas Business Model: Revenue Streams

You're looking at the financial foundation of Aptorum Group Limited (APM) as of late 2025, and honestly, the revenue streams are heavily weighted toward financing activities right now, which is typical for a clinical-stage biopharma before product approval. The core business model relies on securing capital to fund its development pipeline and strategic acquisitions.

The most concrete revenue-adjacent activity has been capital raising through equity offerings. You saw a significant move in October 2025 to bolster the balance sheet ahead of the DiamiR Biosciences Corp. merger. This wasn't a one-off event this year, either.

Here's a quick look at the recent financing events:

Date	Type of Offering	Gross Proceeds (Upfront)	Shares Sold	Price Per Share	Potential Additional Proceeds (Warrants)
October 2025	Registered Direct Offering	$2.0 million	1,000,000 Class A ordinary shares	$2.00	Up to $4 million
January 2025	Registered Direct Offering	$3.0 million	1,535,000 Class A Ordinary Shares	$2.00	N/A (Warrant details not specified in this result)

The October 2025 capital raise, with H.C. Wainwright & Co. as the placement agent, was explicitly intended to fund expenses related to the previously announced merger with DiamiR Biosciences Corp. and for general working capital. It's important to note that the warrants issued in that October deal are exercisable at $2.00 per share and expire twenty-four months from the effective date of a registration statement. As of late 2025, the company maintains a moderate debt level with a debt-to-equity ratio of 0.15.

The current commercial revenue picture is minimal, as is common when a company is pre-commercialization. While specific H1 2025 net loss figures aren't in my latest data, the most recent reported loss was a net loss of $2.7 million for the six months ended June 30, 2024, which was an improvement from the $6.6 million loss in the same period of 2023, driven by budgetary control measures. As of August 22, 2025, the total equity was reported at $21.13 million against total liabilities of $4.35 million. Furthermore, an AI Analyst assessment in October 2025 noted that Aptorum Group's overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns.

Future revenue streams are tied directly to the successful execution of their pipeline and the DiamiR merger. These streams are expected to materialize from:

• Future sales of approved therapeutic assets in oncology and infectious diseases.
• Revenue from biopharma services and diagnostic sales following the DiamiR Biosciences Corp. merger, which was agreed upon on July 14, 2025.
• Potential future milestone payments derived from the 11 exclusively licensed technologies Aptorum Group has obtained in areas like neurology and surgical robotics.

The DiamiR Biosciences merger, an all-stock deal where DiamiR shareholders are set to receive 70% of the combined company's common stock, is key to unlocking the diagnostics revenue component. DiamiR specializes in innovative blood-based tests for brain health, including the APOE Genotyping test. If onboarding takes 14+ days, churn risk rises, but for Aptorum Group Limited, the immediate focus is closing this transaction to transition from pure financing to product-driven revenue generation.

Finance: draft 13-week cash view by Friday.